Progenics Pharmaceuticals (FRA:PGP) LT-Debt-to-Total-Asset : 0.46 (As of Mar. 2020)

View and export this data going back to 1997. Start your Free Trial

What is Progenics Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Progenics Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2020 was 0.46.

Progenics Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2019 (0.32) to Mar. 2020 (0.46). It may suggest that Progenics Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Progenics Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Progenics Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progenics Pharmaceuticals LT-Debt-to-Total-Asset Chart

Progenics Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.25

0.32

0.23

0.39

Progenics Pharmaceuticals Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.32	0.34	0.38	0.39	0.46

Progenics Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Progenics Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

LT Debt to Total Assets (A: Dec. 2019 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2019 )	/	Total Assets (A: Dec. 2019 )
	=	42.224	/	107.523
	=	0.39

Progenics Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2020 is calculated as

LT Debt to Total Assets (Q: Mar. 2020 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2020 )	/	Total Assets (Q: Mar. 2020 )
	=	40.723	/	89.001
	=	0.46

Progenics Pharmaceuticals (FRA:PGP) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Progenics Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Progenics Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Progenics Pharmaceuticals (FRA:PGP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progenics Pharmaceuticals Inc (FRA:PGP) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

One World Trade Center, Suite J, 47th Floor, New York, NY, USA, 10007

Website

http://www.progenics.com

Progenics Pharmaceuticals Inc is an oncology company focused on developing and commercializing targeted medicines and artificial intelligence to treat cancer. Its portfolio includes AZEDRA (to treat malignant and recurrent pheochromocytoma and paraganglioma); 1404 and PyL (imaging agents for prostate cancer); 1404 Index and PyL (analytical tools for analysis and indexing of images for prostate cancer); 1095 (treatment of metastatic prostate cancer); PSMA ADC (treatment of metastatic castration-resistant prostate cancer); and EXINI boneBSI (an analytical Bone Scan Index tool from bone scintigraphy images, currently sold in Europe and Japan). Its partnered products are RELISTOR (sold in the U.S., EU, Australia, and Canada) to treat opioid-induced constipation, and the PRO 140 HIV treatment.

Progenics Pharmaceuticals (FRA:PGP) Headlines

From GuruFocus

PGP Statement on SEC Settlement

By sperokesalga sperokesalga • 06-16-2023